^
    4ms
    ACTM-838-01: A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=35, Recruiting, Actym Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    ACTM-838
    8ms
    A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=35, Not yet recruiting, Actym Therapeutics, Inc.
    New P1 trial • Metastases
    |
    ACTM-838
    over1year
    ACTM-838, a novel immunotherapy that enriches in solid tumors after IV dosing and comprehensively reverses the immunosuppressive TME to promote durable anti-tumor immunity (AACR 2023)
    Analyses of public RNAseq datasets from patients with primary or metastatic disease revealed cancer types with high levels of myeloid infiltration and adenosine enrichment, suggesting that ACTM-838 efficacy could provide benefit in these indications.ACTM-838 is a novel immunotherapy delivering IL-15plex + eSTING payloads to phagocytic APCs, inducing a durable anti-tumor immune response, after IV dosing. It possesses a compelling safety profile, and is currently in IND-enabling, preclinical development.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • STING (stimulator of interferon response cGAMP interactor 1) • IL15 (Interleukin 15)
    |
    ACTM-838